当前位置:首页 - 行情中心 - 荣昌生物(688331) - 财务分析

荣昌生物

(688331)

  

流通市值:188.86亿  总市值:653.66亿
流通股本:1.63亿   总股本:5.64亿

荣昌生物(688331)财务分析

净利润 + 每股收益
------
  • 净利润(亿元)
  • 每股收益(元)

    截至2026年第一季度实现净利润3.28亿元,每股收益0.58元。

股东权益 + 未分配利润
------
  • 股东权益(亿元)
  • 未分配利润(亿元)

    截至2026年第一季度最新股东权益392846.47万元,未分配利润-323995.92万元。

总资产 + 负债
------
  • 总资产(亿元)
  • 负债(亿元)

    截至2026年第一季度最新总资产736519.39万元,负债343672.93万元。

利润表
报告期2026-03-312025-12-312025-09-302025-06-30
营业总收入656,214,449.913,251,051,061.931,719,833,029.781,097,953,438.31
营业总成本696,878,783.643,189,186,995.422,268,418,316.441,547,735,633.21
其他经营收益
营业利润330,170,273.88722,605,872.09-537,269,154.58-441,154,140.6
利润总额328,493,639.92710,398,488.34-550,700,575.38-449,568,663.07
净利润328,007,104.92709,649,797.14-550,700,575.38-449,568,663.07
每股收益
其他综合收益330,879.6452,652,126.8749,592,840.3230,010,415.8
综合收益总额328,337,984.56762,301,924.01-501,107,735.06-419,558,247.27
资产负债表
报告期2026-03-312025-12-312025-09-302025-06-30
流动资产:
流动资产合计4,112,057,982.683,981,885,253.422,719,142,876.942,698,160,087.74
非流动资产:
非流动资产合计3,253,135,923.083,266,187,035.553,257,987,007.183,152,198,029.18
资产总计7,365,193,905.767,248,072,288.975,977,129,884.125,850,358,116.92
流动负债:
流动负债合计2,600,531,250.452,787,458,4942,832,798,494.682,547,894,786.18
非流动负债:
非流动负债合计836,198,001.62851,792,137.4824,248,325.8944,972,759.65
负债合计3,436,729,252.073,639,250,631.43,657,046,820.483,492,867,545.83
所有者权益(或股东权益):
归属于母公司股东权益合计3,928,464,653.693,608,821,657.572,320,083,063.642,357,490,571.09
股东权益合计3,928,464,653.693,608,821,657.572,320,083,063.642,357,490,571.09
负债和股东权益合计7,365,193,905.767,248,072,288.975,977,129,884.125,850,358,116.92
现金流量表
报告期2026-03-312025-12-312025-09-302025-06-30
经营活动产生的现金流量:
经营活动现金流入小计770,608,371.942,719,241,387.372,255,935,870.871,077,583,670.92
经营活动现金流出小计759,290,367.992,666,289,491.992,038,878,436.931,323,122,926.19
经营活动产生的现金流量净额11,318,003.9552,951,895.38217,057,433.94-245,539,255.27
投资活动产生的现金流量:
投资活动现金流入小计664,553,376.082,164,959,117.361,062,794,914.72261,654,258.4
投资活动现金流出小计643,973,532.192,370,607,014.351,342,340,631.06380,704,078.26
投资活动产生的现金流量净额20,579,843.89-205,647,896.99-279,545,716.34-119,049,819.86
筹资活动产生的现金流量:
筹资活动现金流入小计191,190,318.712,849,724,870.072,117,271,291.071,974,875,468.43
筹资活动现金流出小计273,722,902.492,297,766,584.861,746,302,543.741,094,539,402.98
筹资活动产生的现金流量净额-82,532,583.78551,958,285.21370,968,747.33880,336,065.45
汇率变动对现金及现金等价物的影响-5,332,945.61-4,193,799.09-620,373.83-4,276,762.99
现金及现金等价物净增加额-55,967,681.55395,068,484.51307,860,091.1511,470,227.33
期末现金及现金等价物余额1,098,630,846.381,154,598,527.931,067,390,134.521,271,000,270.75
补充资料:
现金及现金等价物的净增加额-395,068,484.51-511,470,227.33
最新报告期:2026-04-29
研究机构分析师预测每股收益(元)更新日
2026年2027年2028年
华泰证券代雯,李航,袁中平7.510.841.952026-04-29
西部证券李梦园7.630.991.992026-04-10
东海证券杜永宏6.921.102.312026-04-02
国投证券连国强4.970.681.732026-04-01
华泰证券代雯,李航,袁中平7.510.841.952026-03-30
TOP↑